Zydus Lifesciences Limited (NSE:ZYDUSLIFE)

Zydus Lifesciences Financials Overview

Financials in millions INR. Fiscal year is April - March.

Revenue & Profits

Chart

Fiscal Year	TTM	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Jun 30, 2026	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Revenue Revenue Growth	285,917	271,484	232,415	195,474	172,374	151,099
Revenue Growth	21.11%	16.81%	18.90%	13.40%	14.08%	4.90%
Gross Profit Gross Profit Growth	206,178	196,248	167,031	131,537	107,667	94,242
Operating Income Operating Income Growth	53,494	58,249	59,602	45,392	28,528	24,741
Net Income Net Income Growth	45,130	50,400	45,255	38,595	19,603	44,873
Earnings Per Share EPS Growth	44.86	50.09	44.97	38.14	19.30	43.83
EPS Growth	-1.28%	11.37%	17.92%	97.61%	-55.97%	110.32%

Revenue by Segment

Chart

Fiscal Year	TTM	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Jun 30, 2026	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Pharmaceuticals (excl. Medical Technologies) Pharmaceuticals (excl. Medical Technologies) Growth	229,960	224,121	205,415	-	-	-
Consumer Products Consumer Products Growth	45,324	39,540	26,976	23,120	22,448	19,788
Medical Technologies Medical Technologies Growth	10,633	7,823	24	-	-	-
Total Total Growth	285,917	271,484	232,415	195,474	172,374	151,099

Cash & Debt

Chart

Fiscal Year	Current	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Jun 30, 2026	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Cash & Investments Cash & Investments Growth	49,711	49,711	56,416	13,530	11,924	39,735
Total Debt Total Debt Growth	125,146	125,146	32,180	8,219	11,951	42,210
Net Cash (Debt) Net Cash Growth	-75,435	-75,435	24,236	5,311	-27	-2,475
Net Cash Growth	-	-	356.34%	-	-	-
Net Cash Per Share Net Cash Per Share Growth	-74.98	-74.97	24.09	5.25	-0.03	-2.42

Cash Flow & CapEx

Chart

Fiscal Year	TTM	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Jun 30, 2026	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Operating Cash Flow Operating Cash Flow Growth	-	21,166	67,811	31,963	26,888	21,045
Capital Expenditures CapEx Growth	-	-33,940	-16,937	-9,066	-10,309	-12,026
Free Cash Flow Free Cash Flow Growth	-	-12,774	50,874	22,897	16,579	9,019
Free Cash Flow Growth	-	-	122.19%	38.11%	83.82%	-63.03%

Margins

Chart

Fiscal Year	TTM	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Jun 30, 2026	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Gross Margin	72.11%	72.29%	71.87%	67.29%	62.46%	62.37%
Operating Margin	18.71%	21.46%	25.64%	23.22%	16.55%	16.37%
Pretax Margin	21.36%	24.75%	26.18%	25.21%	15.57%	19.09%
Profit Margin	15.78%	18.57%	19.47%	19.74%	11.37%	29.70%
FCF Margin	-	-4.71%	21.89%	11.71%	9.62%	5.97%

Dividends

Chart

Fiscal Year	Current	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Aug 15, 2026	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
Dividend Per Share Dividend Per Share Growth	1.000	1.000	11.000	3.000	6.000	2.500
Dividend Per Share Growth	-90.91%	-90.91%	266.67%	-50.00%	140.00%	-28.57%
Dividend Yield	0.09%	0.11%	1.26%	0.30%	1.25%	0.74%

Valuation

Chart

Fiscal Year	Current	FY 2026	FY 2025	FY 2024	FY 2023	FY 2022
Period Ending	Aug 15, 2026	Mar 31, 2026	Mar 31, 2025	Mar 31, 2024	Mar 31, 2023	Mar 31, 2022
PE Ratio	25.31	17.39	19.71	26.26	25.38	7.95
Forward PE	26.54	20.54	19.01	28.46	21.39	16.57
P/FCF Ratio	-	-	17.53	44.27	30.01	39.56
PS Ratio	3.96	3.23	3.84	5.19	2.89	2.36

Data Source: S&P Global Market Intelligence Last updated: Jun 30, 2026

Financial data is provided by S&P Global Market Intelligence and updates within hours after each earnings release, which is every three months for this company.

Update frequency:

Quarterly

Last checked:

Aug 15, 2026

Data Sources Report a data error